CA
NZ
UK
AU
IND
US
…
Yubo International Biotech Limited, through its subsidiaries, focuses on the research and development, and application of endometrial stem cells. It offers healthcare products for respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products; and stem cell related services, including cell testing and health management consulting services under the VIVCELL brand. The company is headquartered in Beijing, China.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Yubo International Biotech Limited is an OTC Pink–listed firm that reports activity in biotechnology but provides limited public detail on products, operations and financials. Long-term growth may depend on successful R&D, regulatory approvals and commercialization or strategic partnerships, and investors may find the company attractive if it delivers clear milestones and improved disclosure.
Principal risks are limited disclosure, low liquidity, early-stage execution and regulatory risk common to thinly traded biotech issuers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-02-28 | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-02-28 | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 |
| Income before tax | -1.20M | -1.54M | -0.71M | -0.13M | -0.15M |
| Net income | -1.20M | -1.54M | -0.71M | -0.13M | -0.15M |
| Selling general administrative | 1.04M | 1.31M | 0.54M | 0.03M | 0.05M |
| Selling and marketing expenses | 0.01M | 0.18M | 0.66M | - | - |
| Gross profit | 0.05M | 0.82M | 1.24M | - | - |
| Reconciled depreciation | 0.03M | 0.02M | 0.01M | - | - |
| Ebit | -1.21M | -1.54M | -0.71M | -0.23M | -0.05M |
| Ebitda | -1.18M | -1.52M | -0.70M | -0.03M | -0.05M |
| Depreciation and amortization | 0.03M | 0.02M | 0.01M | - | - |
| Operating income | -1.21M | -1.54M | -0.71M | -0.03M | -0.05M |
| Other operating expenses | 1.31M | 2.79M | 2.07M | 0.12M | 0.05M |
| Interest expense | 0.00M | 427.00M | -0.10M | 0.00M | 0.10M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | 0.00M | 0.00M | -0.00M | -0.10M | -0.10M |
| Income tax expense | -0.00M | -0.00M | 0.00M | - | - |
| Total revenue | 0.10M | 1.24M | 1.35M | 0.00M | 0.00M |
| Total operating expenses | 1.26M | 2.36M | 1.95M | 0.03M | -0.05M |
| Cost of revenue | 0.05M | 0.42M | 0.11M | - | - |
| Total other income expense net | 0.00M | 0.00M | -0.00M | - | -0.10M |
| Net income from continuing ops | -1.20M | -1.54M | -0.71M | -0.13M | -0.15M |
| Net income applicable to common shares | - | -1.54M | -0.71M | -0.23M | -0.15M |
| Breakdown | 2023-02-28 | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-02-28 | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 |
| Total assets | 2.35M | 4.59M | 2.44M | 0.00M | 0.00M |
| Intangible assets | 0.07M | 0.04M | 0.05M | - | - |
| Other current assets | 0.36M | 0.31M | 0.03M | - | - |
| Total liab | 2.91M | 4.72M | 1.28M | 1.80M | 1.67M |
| Total stockholder equity | -0.57M | -0.13M | 1.17M | -1.80M | -1.66M |
| Other current liab | 1.11M | 1.26M | 0.09M | 0.09M | 0.04M |
| Common stock | 0.12M | 0.12M | 0.12M | 0.00M | 0.00M |
| Capital stock | 0.12M | 0.12M | 0.12M | - | - |
| Retained earnings | -3.69M | -2.49M | -0.94M | -0.23M | -28.95M |
| Other assets | - | 0.15M | 0.09M | 0.08M | - |
| Cash | 0.02M | 0.03M | 1.38M | 0.00M | 0.00M |
| Total current liabilities | 2.52M | 2.79M | 1.28M | 0.36M | 1.67M |
| Current deferred revenue | 0.46M | 0.48M | 0.77M | - | - |
| Net debt | 0.77M | 2.67M | -1.07M | 1.41M | 1.28M |
| Short term debt | 0.40M | 0.77M | 0.32M | - | 1.28M |
| Short long term debt | - | - | - | 1.41M | 1.28M |
| Short long term debt total | 0.79M | 2.69M | 0.32M | - | 1.28M |
| Other stockholder equity | 2.94M | 2.12M | 1.99M | -0.00M | 27.29M |
| Property plant equipment | - | 3.34M | 0.39M | 0.58M | - |
| Total current assets | 0.75M | 1.06M | 1.91M | 0.46M | 0.00M |
| Net tangible assets | - | -0.17M | 1.11M | 0.49M | -1.66M |
| Net receivables | 0.35M | 0.56M | 0.43M | 0.40M | - |
| Inventory | 0.32M | 0.16M | 0.07M | - | - |
| Accounts payable | 0.55M | 0.28M | 0.10M | 0.35M | 0.34M |
| Accumulated other comprehensive income | 0.07M | 0.12M | 0.00M | - | - |
| Non currrent assets other | 0.12M | 0.15M | 0.09M | - | - |
| Non current assets total | 1.60M | 3.53M | 0.54M | 0.00M | 0.00M |
| Capital lease obligations | 0.79M | 2.69M | 0.32M | - | - |
| Breakdown | 2023-02-28 | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-02-28 | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 |
| Investments | -0.04M | -0.56M | -0.10M | 0.00M | 0.00M |
| Change to liabilities | - | 0.17M | 0.10M | 0.00M | 0.12M |
| Total cashflows from investing activities | - | -0.56M | -0.10M | -0.04M | - |
| Net borrowings | - | - | - | 0.02M | 0.03M |
| Total cash from financing activities | 0.00M | 0.13M | 1.38M | 0.72M | 0.03M |
| Change to operating activities | - | 0.57M | 0.77M | -0.45M | - |
| Net income | -1.20M | -1.54M | -0.71M | -0.23M | -0.15M |
| Change in cash | -0.01M | -1.36M | 1.38M | 0.00M | 0.00M |
| Begin period cash flow | 0.03M | 1.38M | 0.00M | 0.00M | 0.00M |
| End period cash flow | 0.02M | 0.03M | 1.38M | 0.00M | 0.00M |
| Total cash from operating activities | 0.07M | -1.02M | 0.10M | -0.68M | -0.03M |
| Issuance of capital stock | - | 0.00M | 0.75M | - | - |
| Depreciation | 0.03M | 0.02M | 0.01M | 0.00M | - |
| Change to inventory | -0.16M | -0.10M | -0.07M | -0.07M | - |
| Change to account receivables | 0.11M | -0.16M | -0.00M | -0.00M | - |
| Other cashflows from financing activities | -0.04M | 0.13M | 0.63M | - | 0.03M |
| Change to netincome | - | 0.01M | 0.01M | 0.01M | - |
| Capital expenditures | 0.04M | 0.56M | 0.10M | 0.04M | 0.00M |
| Change in working capital | 1.25M | 0.49M | 0.80M | 0.11M | -0.15M |
| Other non cash items | - | 0.01M | - | - | 0.26M |
| Free cash flow | 0.03M | -1.59M | 0.00M | -0.02M | -0.03M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| YBGJ Yubo International Biotech Limited |
- -% |
0.01 | - | - | 46.53 | 61.23 | 47.28 | -62.93 |
| ISRG Intuitive Surgical Inc |
-8.88 1.97% |
440.65 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
-2.56 1.26% |
200.18 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
-1.98 1.94% |
99.87 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
0.83 0.39% |
215.35 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
Yubo International Biotech Limited, through its subsidiaries, focuses on the research and development, and application of endometrial stem cells. It offers healthcare products for respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products; and stem cell related services, including cell testing and health management consulting services under the VIVCELL brand. The company is headquartered in Beijing, China.
| Name | Title | Year Born |
|---|---|---|
| Mr. Jun Wang | CEO, Pres & Director | 1968 |
| Ms. Lina Liu | CFO, Treasurer & Sec. | 1981 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...